Omapatrilat is the most clinically advanced member of a class of cardiovascular drugs known as
vasopeptidase inhibitors, that simultaneously inhibit neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), two key enzymes that work together in the cardiovascular system to control heart function and blood pressure.